Inferra AIResearch Tools

Inferra AI / Company / LH

Labcorp

LH · Health Care

Last earnings Oct 28, 2026

Key results

Adjusted operating incomequarter

9%

(4) Adjusted Operating Income grew 9% year over year driven by organic demand.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

AI analysis

Q3 2025 · reported Oct 28, 2025

Based on: Earnings release + parent 8-K — transcript not held

Headline figures

MetricQ3 2025Prior qtrYear ago
Adjusted operating income9%——

EX-99 · Oct 28, 2025

Guidance · company-stated

Revenue

“Labcorp Enterprise (1)(2) $13.01 7.5%”

Adjusted EPS

“$14.57 $16.05”

Free Cash Flow

“$1.10 $1.13”

Guidance stated in the release's Business Outlook table for 2025; no direction stated — figures as stated in the table.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Dividend$0.72

On October 8, 2025, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on December 11, 2025, to stockholders of record at the close of business on November 26, 2025.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Labcorp Q3 2025 — (4) Adjusted Operating Income grew 9% year over year driven by organic demand.

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Revenue: “Revenue Labcorp Enterprise (1)(2) $13.01 7.5%”

Adjusted EPS: “Adjusted EPS $14.57 $16.05”

Free Cash Flow: “Free Cash Flow $1.10 $1.13”

Revenue (“2025”)
“Revenue Labcorp Enterprise (1)(2) $13.01 7.5%”

Adjusted EPS (“2025”)
“Adjusted EPS $14.57 $16.05”

Free Cash Flow (“2025”)
“Free Cash Flow $1.10 $1.13”

Guidance stated in the release's Business Outlook table for 2025; no direction stated — figures as stated in the table.

Capital allocation

On October 8, 2025, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on December 11, 2025, to stockholders of record at the close of business on November 26, 2025.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

In the quarter, Labcorp repurchased $25 million of common stock.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Capital Allocation Summary At the end of the quarter, Labcorp's cash and cash equivalents balance was $598 million and total debt was $5.58 billion.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

During the quarter, the company invested $268.4 million in acquisitions and partnerships, paid out $59.9 million in dividends, and repurchased $25.0 million of stock.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Strategy & priorities

We advanced our strategy by forming new partnerships with health systems and regional laboratories, introducing innovative tests in key specialty areas and leveraging science and technology to improve customer experience and operational efficiency.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

We expect to finish the year strong as we remain focused on delivering value to our customers and shareholders.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

C autionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2025 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including the projected impact of global economic and market conditions on the company's businesses, operating results, cash flows and or financial condition, (iii) future business strategies, (iv) expected savings, synergies and other benefits to the Company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Risks & headwinds

Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC.

SEC original ↗Labcorp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Documents

Earnings deck slides

0 decks with slide view

Labcorp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Labcorp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Labcorp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

75 documents

Earnings releases

17 documents

Presentations

3 documents

Transcripts

0 documents

No transcripts for Labcorp are held in this edition of the library.

Mentioned by

4 companies

Other tracked companies whose held documents mention Labcorp by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.